



Advancing Transfusion and  
Cellular Therapies Worldwide

# AABB Initiatives and Priorities

## AABB/FDA Liaison Committee Meeting

Zbigniew “Ziggy” M. Szczepiorkowski, MD, PhD  
President  
January 31, 2017

Who are we...?

...through our vision, mission and core values



Advancing Transfusion and  
Cellular Therapies Worldwide

# AABB Vision

- Making transfusion medicine and cellular therapies safe, available and effective worldwide.

# AABB Mission

- AABB is the global leader in standards development, accreditation and implementation of quality systems in transfusion medicine and cellular therapies.
- AABB has an unwavering focus on donor and patient safety. We accomplish it by translating knowledge into solutions that shape the field of transfusion medicine and cellular therapies.
- AABB brings together those engaged in transfusion medicine and cellular therapies. AABB creates a unique learning environment, including our signature Annual Meeting, that inspires and enables research, innovation, discovery and excellence.



# AABB Core Values

- Respect: Respect for our members, as well as the donors and patients we serve.
- Integrity: Dedication to adhering to the highest ethical standards of practice.
- Transparency: Maintaining open and honest communication with our membership and the public.
- Excellence: Striving to promote best practices for the professional community we serve and for the care of patients and donors.
- **RITE** values deliver **trust**.



A few thoughts for today...



Advancing Transfusion and  
Cellular Therapies Worldwide

# Donor Health and Safety Committee

- AABB has recently established this committee in recognition of critical questions regarding our donors.
- The committee is charged with addressing safety issues affecting both blood and cellular therapy donors.
- Some of the topics discussed today are part of the charges of this Committee.

# Regulatory Strategy Committee

- The AABB BOD recognized the need for creation of a committee which could proactively work on issues important to the community we represent.
- This is a Board level committee.
- The actual charges and make up of the committee are being finalized but the report of the exploratory phase has been presented to the BOD.
- Some immediate opportunities include work with legislative and executive branch on the vision for healthcare in the US.






*Advancing Transfusion and  
Cellular Therapies Worldwide*

# Risk Based Decision Making (RBDM) Framework - AABB/CBS Babesia application

**Slides courtesy of Dr. Judie Leach Bennett and  
Ms. Sheila Ward**



Global Sharing. Local Results.

- RESOURCES
- PUBLICATIONS
- NEWS
- ABOUT ABO
- CONTACT US
- MEMBER SIGN-IN

# Global Sharing. Local Results.

[Home](#) | [Resources](#) | [Risk-Based Decision-Making](#) | [Development of the Risk-Based Decision-Making Framework](#)

## Development of the Risk-Based Decision-Making Framework

The Risk-Based Decision-Making Framework was created under the auspices of the ABO. It grew out of a series of activities that began with the International Consensus Conference on Risk-Based Decision-Making for Blood Safety in Toronto in 2010.

The consensus statement that emerged from these discussions acknowledged that risk is

### RISK-BASED DECISION-MAKING

[DEVELOPMENT OF THE RISK-BASED DECISION-MAKING FRAMEWORK](#)

[THE RISK-BASED DECISION-MAKING FRAMEWORK](#)

[STAKEHOLDER CONSULTATION](#)

risk-qrg.pdf

1-18-2017 Lab O....docx

K1L23A NTO.pdf

K1L23A.pdf

MAFWebFundOve...pdf

Show all



Advancing Transfusion and Cellular Therapies Worldwide

# RBDM Framework

The framework's objectives are to:

- Optimise the safety of the blood supply while recognising that **elimination of all risk is not possible.**
- Allocate resources in **proportion to the magnitude and seriousness of the risk** and the effectiveness of the interventions to reduce risk.
- Assess and **incorporate the social, economic, and ethical factors** that may affect decisions about risk.



The new  
decision-making  
paradigm  
envisioned for  
blood safety  
decision-making

---

**A health sector focus**

---

**A consistent, standardised  
approach to decision-making**

---

**Evidence-based decisions  
using risk assessment tools**

---

**Acceptable risk based on  
societal considerations**


---

**Multiple sectors included in  
the decision-making process**





# AABB Babesia Workgroup



- Two face to face meetings
- September 2016 – steps 1-3
- December 2016 – steps 4-6
- Currently working on stakeholder engagement with final report in April 2017
- In house expertise in RBDM
- Possible Future Projects for RBDM:
  - Iron in donors;
  - Geographical deferral
  - Other

# In conclusion:

- AABB is committed to patient and donor safety and pursues a variety of approaches to accomplish this goal.
- AABB fully supports RBDM framework to consistently address decision making in highly regulated environments.
- AABB works with all stakeholders to advance its vision.